WAIKOLOA, Hawaii — In this Healio Video Perspective from Retina 2026, Jorge Calzada, MD, discusses IOP stabilization during vitrectomy.{{VIDEO}}“Most vitrectomy surgery involves an infusion pressure through our infusion cannula that different doctors s…
Insights from 2025 International Study of Dry Eye Sufferers
Dry eye disease affects millions of people globally. Yet despite its prevalence, it remains underrecognized, underdiagnosed and undertreated.The 2025 International Study of Dry Eye Sufferers, called Needs Unmet in Dry Eye: Symptoms, Treatment and Sever…
Q&A: Protection pointers as ICE activity increases in health care settings
Health care providers may encounter immigration officers in their hospitals and practices, but they can take steps to prepare themselves for these interactions, staying safe and legally compliant, according to an expert.The past year has been marked by…
Omidenepag isopropyl may increase myopia in glaucoma
Omidenepag isopropyl eye drops may increase nearsightedness in patients with glaucoma, leading to myopic shifts of 0.75 D or more, according to a study published in Journal of Glaucoma.“Omidenepag isopropyl is a relatively new glaucoma medication that …
PRAME TCR Therapy Delivers Breakthrough in Uveal Melanoma
Dr Teresa Amaral reviews ESMO 2025 data showing unprecedented response rates with PRAME-directed TCR therapy in metastatic uveal melanoma. Medscape Oncology
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
MISSOULA, Mont.–(BUSINESS WIRE)–OSRX remains licensed and operational in California, continuing uninterrupted access to compounded ophthalmic medications.